Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.50 Analyst target: $8.08 Upside: 130.86%
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
See the full interactive analysis & chart →Informational only — not investment advice.